Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Nov;26(11):1851-5.
doi: 10.1007/s10067-007-0588-z. Epub 2007 Feb 27.

Outcome of patients having dermatomyositis admitted to the intensive care unit

Affiliations
Case Reports

Outcome of patients having dermatomyositis admitted to the intensive care unit

Yaniv Sherer et al. Clin Rheumatol. 2007 Nov.

Abstract

Patients having systemic rheumatic diseases constitute a small percentage of admissions to the medical intensive care units (ICUs). Dermatomyositis (DM) is one of the rheumatic diseases that have secondary complications that may lead to a critical illness requiring hospitalization in the ICU. Herein, we present the features, clinical course, and outcome of critically ill patients having DM who were admitted to the ICU. The medical records of six DM patients admitted to the ICU in a large tertiary hospital in a 12-year period were reviewed. The mean age of patients at time of admission to the ICU was 38 (range 16-37). Mean disease duration from diagnosis to admission to the ICU was 1.6 years (range 1 month-8 years), while the main reason for admission to the ICU was acute respiratory failure. Two of six patients died during the hospitalization. The main causes of death were respiratory complications and sepsis. The outcome of DM patients admitted to the ICU was generally not different from the outcome of other patients hospitalized in the ICU. The main reason for hospitalization was acute respiratory failure. As there are many reasons for respiratory failure in DM, an early diagnosis and aggressive appropriate treatment may help to further reduce the mortality in these patients.

PubMed Disclaimer

References

    1. Rheumatology (Oxford). 2000 Aug;39(8):914-6 - PubMed
    1. Semin Neurol. 1994 Jun;14(2):137-45 - PubMed
    1. N Engl J Med. 1975 Feb 13;292(7):344-7 - PubMed
    1. J Rheumatol. 1985 Dec;12(6):1140-8 - PubMed
    1. N Engl J Med. 1991 Nov 21;325(21):1487-98 - PubMed

Publication types

LinkOut - more resources